Olmesartan/Hidroclorotiazida Kern Pharma (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan/Hidroclorotiazida is an antihypertensive combination that lowers elevated blood pressure in patients with primary hypertension.

• Hypertension: reduces systolic and diastolic blood pressure and helps prevent cardiovascular complications associated with uncontrolled hypertension.

• Olmesartan medoxomil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits the Na⁺/Cl⁻ symporter in the distal convoluted tubule, promoting sodium and water excretion. The dual action results in decreased peripheral vascular resistance and reduced plasma volume, producing an overall antihypertensive effect.

Common Side Effects

• Dizziness: feeling light‑headed or unsteady.
• Headache: mild to moderate head pain.
• Fatigue: unusual tiredness or lack of energy.
• Increased urination: more frequent need to void.
• Electrolyte imbalance: changes in potassium or sodium levels.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Severe hypotension: dangerously low blood pressure.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: elevated potassium levels.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Pancreatitis: inflammation of the pancreas.
• Blood dyscrasias: abnormal blood cell counts.

Before initiating therapy, consider the following precautions:

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Renal function assessment: evaluate creatinine and eGFR, especially in patients with pre‑existing kidney disease.
• Electrolyte surveillance: check potassium and sodium levels regularly.
• Hepatic impairment: use with caution in severe liver disease.
• Diabetes mellitus: monitor glucose as diuretics may affect glycaemic control.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Hidroclorotiazida may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren: combined use can cause excessive potassium rise and renal dysfunction.
• ACE inhibitors or other ARBs: additive hypotensive effect and risk of hyperkalemia.
• Lithium: increased lithium levels leading to toxicity.
• Potassium‑sparing diuretics or supplements: risk of severe hyperkalemia.
• NSAIDs (high dose): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may require dose adjustment to prevent hypotension.
• Loop diuretics: combined diuretic effect can cause volume depletion.
• CYP450 inhibitors (e.g., fluconazole): may modestly increase olmesartan levels.